GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc (GSK) reported that on September 8, 2026 it granted a conditional share award to Roanne Parry, Chief People Officer and Executive Committee member, under the GlaxoSmithKline 2017 Performance Share Plan. The award covers 85,714 Ordinary Shares of 31¼ pence each, with performance measured over the three financial years from January 1, 2026 to December 31, 2028. Vesting will depend on achievement against performance measures set by the Remuneration Committee, aligned with those of other 2026 Executive Committee awards, and any portion that does not vest at the end of the period will lapse. Dividends will accrue during the performance period but only vest in line with the final vesting outcome.
GSK plc (GSK), through its wholly owned financing subsidiary GlaxoSmithKline Capital Inc., is conducting a multi‑series U.S. dollar senior notes offering, including several fixed‑rate tranches and a floating‑rate tranche, all fully and unconditionally guaranteed by GSK plc and intended to be listed on the New York Stock Exchange or another recognized exchange.
The notes will be senior unsecured obligations of GSK Capital Inc., pari passu with its other senior unsecured debt, and structurally subordinated to liabilities at GSK’s operating subsidiaries. Fixed‑rate series include issuer call options (with make‑whole and par‑call structures), while the floating‑rate notes pay interest quarterly at Compounded SOFR plus a margin, subject to detailed benchmark‑transition mechanics.
GSK expects to use the net proceeds to repay borrowings under an Acquisition Facility incurred for the completed acquisition of Nuvalent, Inc., and for general corporate purposes, including refinancing maturing debt. The filing highlights risks such as potentially limited trading markets for the notes, the possibility of early redemption, SOFR‑related benchmark and liquidity risks, and the absence of covenants limiting additional indebtedness at GSK or its subsidiaries.
GSK plc (GSK) reported Q2 2026 turnover of £8.41 billion, up 5% at both AER and CER, driven by Specialty Medicines (up 14% to £3.78 billion) and Vaccines (up 9% to £2.28 billion), while General Medicines declined 9% to £2.34 billion.
Total operating profit fell to £481 million, down 76%, and Total EPS to 10.8p, down 69%, mainly due to £1.33 billion impairment for camlipixant and £371 million for terminated Alector assets, plus higher contingent consideration charges. Core EPS rose to 50.5p from 46.5p, reflecting underlying growth and mix improvements.
Free cash flow was strong at £1.99 billion in Q2 and £2.81 billion in H1, supporting a Q2 dividend of 17p per share and completion of the £2 billion share buyback. Net debt increased to £15.13 billion after acquisitions, dividends and buybacks. GSK launched a three‑year “Accelerate Growth” programme targeting £1.9 billion annual savings by 2029 for £2.4 billion in costs, largely to reinvest in a late‑stage pipeline of 62 assets, including 19 in phase III.
GSK plc (GSK) reported its share capital and voting rights position as at 31 August 2026. The issued share capital consisted of 4,316,302,379 Ordinary Shares of 31¼ pence each, of which 270,881,064 shares were held in treasury.
After excluding treasury shares, the total number of voting rights in GSK was 4,045,421,315. Shareholders may use this voting-rights figure as the denominator when assessing whether they must notify interests or changes in interests under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.
GSK plc (GSK) reported positive phase II results for its investigational mRNA seasonal influenza vaccine and plans to advance the optimised candidate FLUm3HA.b-3NA into a phase III efficacy trial starting in September 2026. In a 971‑adult phase II trial, the vaccine generated higher immune responses against all tested influenza strains than licensed standard‑dose and high‑dose inactivated flu vaccines in younger and older adults, and was generally well tolerated.
The vaccine is designed to target both haemagglutinin (HA) and neuraminidase (NA), the two primary influenza surface antigens, whereas licensed vaccines primarily target HA. The programme is part of GSK’s broader respiratory vaccines research, and the candidate has received US FDA Fast Track designation for the targeted age indication.
GSK plc (GSK) reports a transaction by senior management under its executive savings plan. Maya Martinez-Davis, President, acquired 9.221 notional American Depositary Shares (ADS) of GSK within her GSK Executive Supplemental Savings Plan account at a price of $51.7800 per ADS. The transaction took place on 24 August 2026 on the New York Stock Exchange (XNYS). The filing classifies this as an acquisition of notional ADS rather than a direct market trade.
GSK plc (GSK) reports transactions by President Maya Martinez-Davis in the company’s American Depositary Shares (ADS). On 20 August 2026, she sold 3,916 ADS on the New York Stock Exchange at an aggregated price of $52.1400 per ADS. On 21 August 2026, she sold a further 40,481 ADS at an aggregated price of $52.1437 per ADS, also on the NYSE.
GSK plc (GSK) reports that Japan’s Ministry of Health, Labour and Welfare has granted the first global approval for Hibsago (bepirovirsen), an antisense oligonucleotide, as a functional cure for chronic hepatitis B in adults meeting specific viral and prior-treatment criteria. This is described as the first and only functional cure treatment for chronic hepatitis B approved in Japan, where nearly one million people live with the disease and it contributes to about 4,000 deaths annually. The approval was accelerated by SENKU designation, which recognises innovative medicines with high unmet medical need, and is supported by phase III B-Well data showing a 19% functional cure rate versus 0% on placebo, with an acceptable safety profile. GSK is pursuing additional regulatory submissions for bepirovirsen globally, including in the US.
GSK plc (GSK) reports that the US FDA has accepted for priority review a supplemental Biologics License Application for Jemperli (dostarlimab) as monotherapy in previously untreated stage II and III dMMR/MSI-H locally advanced rectal cancer, with a PDUFA action date in February 2027.
The filing highlights phase II AZUR-1 registrational trial data in 154 patients, where dostarlimab monotherapy achieved a meaningful and sustained 12‑month clinical complete response rate with a safety profile consistent with prior experience across solid tumours. Patients received nine 500 mg intravenous infusions every three weeks over six months.
The submission was also accepted under Project Orbis and is eligible for expedited review under the US National Priority Voucher program, potentially enabling earlier decisions in the US and other participating countries. Jemperli is already a key PD-1-blocking antibody in GSK’s immuno-oncology pipeline but is not currently approved for locally advanced rectal cancer.
GSK plc (GSK) has a notice of proposed sale under Rule 144 filed for the account of officer Maria E Martinez. The notice covers up to 44,397 American Depositary Shares of GSK to be sold through Charles Schwab & Co. on or after 08/20/2026 on the NYSE. The shares were acquired in multiple transactions, including Share Value Plan vesting on 02/19/2025 and 02/09/2026, Performance Share Plan vesting on 02/13/2026, and several dividend reinvestments in 2025–2026.